AARC Supports Special Consideration for Rare Disease Research
July 10, 2009
As Congress works towards reauthorization of the Small Business Innovation Research (SBIR) program, the AARC is joining fellow organizations in supporting rare disease research as an area deserving of “special consideration.”
In a letter to members of the House Committee on Small Business, 60 organizations note small research enterprises are often attracted to rare disease research, but economic difficulties and financial hurdles make it hard for them to move forward with projects aimed at these diseases.
“Special attention from SBIR grants can help to foster significant progress in the search for treatments for these conditions,” notes the letter. “While increased attention on rare disease research from SBIR grants stands to most benefit small biotechnology companies, the true benefit is to the patients that we represent. These individuals depend on the research and development pipeline for new therapies to extend and improve their lives, and we applaud your legislation that will create a favorable environment for support of rare disease research.”